First patient treated in CereVasc clinical trial of eShunt™ System for communicating hydrocephalus
Investigational device has the potential to transform a half-century-old standard of care
News provided by
Share this article
Share this article
BOSTON, Feb. 10, 2021 /PRNewswire/ CereVasc, Inc., a clinical-stage, medical device company developing novel, minimally invasive treatments for neurological diseases, has treated the first patient in a study of its eShunt System, an investigational device intended to treat communicating hydrocephalus (CH), one of the most common neurological conditions worldwide. Representing the first minimally invasive treatment for CH, the eShunt device offers the potential to result in significant benefits over current treatment, a half-century-old neurosurgical procedure associated with frequent failure, infection risk and high costs. Study data will be available in 2021.